Is Bacillus Subtilis Harmful to Humans?

Bacillus subtilis is considered safe for the vast majority of people and carries official safety designations from both the U.S. Food and Drug Administration and the European Food Safety Authority. Documented infections in humans are rare and almost exclusively involve people who are elderly, immunocompromised, or have a damaged gut lining. The story gets more interesting when you look at the specific situations where this otherwise benign bacterium has caused real problems, and at the emerging concern that even “safe” microbes can pick up and pass along antibiotic resistance genes.

What Regulators Have Concluded

At least five strains of B. subtilis have been the subject of “generally regarded as safe” (GRAS) dossiers, and the FDA has issued “no objection letters” for their use in food. The European Food Safety Authority goes further, placing B. subtilis on its Qualified Presumption of Safety list with no restrictions on age or exposure limit. To date, no serious adverse effects have been reported from doses up to 10 billion colony-forming units per day.¹ In clinical testing of a specific probiotic strain (B. subtilis CU1), elderly volunteers who took about 2 billion spores per day for a total of 40 days showed no undesirable effects on liver function, kidney function, blood counts, or vital signs.²

This safety profile stands in sharp contrast to its close relative, Bacillus cereus, which is a well-known cause of food poisoning. Testing has confirmed that B. subtilis strains do not produce the enterotoxins associated with B. cereus, even when researchers specifically looked for them using both genetic and immunological methods.³ That distinction matters because the two bacteria are in the same genus and can be confused in lab identification. When you see “Bacillus” on a food safety report, B. cereus is the one to worry about.

Rare Infections That Have Happened

The clearest documented risk involves people with a damaged gastrointestinal tract. A case report described B. subtilis bacteremia (bacteria in the bloodstream) in a patient who had a gastrointestinal perforation after eating natto, the Japanese fermented soybean food that is loaded with a specific variant of the bacterium. The authors concluded that older or immunocompromised patients could be at risk for bloodstream infection from ingesting natto.⁴

A larger retrospective study at a single hospital found 70 positive blood cultures for B. subtilis out of more than 4,600 total positive cultures over the study period. Of those 70, fully 99% were identified as the natto variant, and only about a third (25 cases) were confirmed as true bacteremia rather than contamination. The confirmed infections included intra-abdominal infections, pneumonia, and urinary tract infections.⁵ The pattern here is telling: in a country where natto consumption is routine, the vast majority of B. subtilis blood isolates traced back to the food-derived variant, and even then the numbers were small.

Perhaps the most cautionary report involves a premature infant. A baby born at roughly 33 weeks developed a catheter-related bloodstream infection during oral probiotic therapy containing B. subtilis. The clinical isolate and the probiotic strain shared identical antibiotic susceptibility profiles, though the authors noted this was not definitive proof the probiotic itself caused the infection. Still, the case underscores that infants with central venous catheters are in a different risk category.⁶ By contrast, a study of antibiotic-exposed preterm infants who received a combination of B. subtilis and another probiotic found no treatment-related adverse events.⁷ The difference likely comes down to whether a direct route into the bloodstream exists, like a central catheter, versus an intact gut barrier.

The Food Poisoning Question

You might encounter B. subtilis on lists of bacteria that have been isolated from food-poisoning cases. The reality is murkier than those lists suggest. While B. subtilis, along with close relatives B. licheniformis and B. pumilus, has occasionally been recovered from episodes of food-associated illness, the actual role of B. subtilis in those episodes was usually uncertain.⁸ As researchers have learned more about the toxins these species can produce, the picture has gotten somewhat clearer, but confirmed outbreaks attributable to B. subtilis remain extraordinarily rare compared to its close cousin B. cereus. In practical terms, if you find B. subtilis in a food sample, it is far more likely to be a harmless environmental contaminant than the cause of anyone’s stomach trouble.

A study examining food vendor samples in Nigeria did detect certain virulence-associated genes in B. subtilis isolates, including genes involved in stress survival (clpX, codY) and nutrient acquisition (purA, purB).⁹ These genes, however, are more about the bacterium’s ability to persist in environments than about producing toxins that make people sick. The dangerous toxin-producing genes (like the emetic and diarrheal toxin genes of B. cereus) were not found in the B. subtilis isolates.

Occupational and Industrial Risks

Where B. subtilis does pose a real, well-documented hazard is in occupational settings, particularly in the detergent and enzyme-manufacturing industries. B. subtilis is the workhorse organism used to produce industrial enzymes like proteases and amylases. Workers who handle concentrated preparations of these enzymes face genuine risks of respiratory sensitization and allergy.

A study of workers at a liquid detergent factory found that about 14% were sensitized to one or more of the enzymes they worked with. Workers in the highest-exposure group reported roughly four times the rate of nasal itching and sneezing compared to the lowest-exposure group, and there was one confirmed case of occupational asthma and two probable cases of occupational rhinitis.¹⁰ The culprit is not the bacterium itself but the enzyme proteins it produces. Detergent manufacturers have implemented control measures to manage this risk, including enclosed handling systems and air monitoring.¹¹

The European Food Safety Authority has also flagged this in its evaluations of B. subtilis as a feed additive, noting that while the bacterium is not an eye or skin irritant, it should be considered a potential respiratory sensitizer, and that inhalation and dermal exposure is a risk for workers handling the product.¹²¹³ If you are taking B. subtilis as a probiotic capsule, this is irrelevant to you. But if you work in manufacturing where you breathe in B. subtilis spores or enzyme dust daily, the respiratory risk is real and well-established.

What B. Subtilis Does in Your Gut

For most people, the relevant question is not whether B. subtilis is dangerous but what it actually does once you swallow it. The bacterium forms tough spores that survive stomach acid easily. Animal research has shown that these spores germinate in the small intestine and may briefly colonize it, though they do not take up permanent residence.¹⁴ Research on strains isolated from the human gut has found that many possess traits useful for surviving there, including the ability to form biofilms, to sporulate in low-oxygen conditions, and to secrete antimicrobial compounds. This has led some microbiologists to argue that B. subtilis is not merely a soil bacterium that accidentally passes through us but a genuine gut commensal that has adapted to intestinal life.¹⁵

One of the more interesting substances B. subtilis produces is surfactin, a lipopeptide with broad antimicrobial activity. Research has shown that surfactin can inhibit both bacterial and viral pathogens and may modify gut microbiota composition in beneficial ways, including reducing populations of harmful E. coli and helping to restore balance after gut disruption.¹⁶ Surfactin also shows activity against Listeria monocytogenes, a particularly dangerous foodborne pathogen, including strains that have developed resistance to other antimicrobials.¹⁷

In a randomized, placebo-controlled trial with elderly volunteers, supplementation with B. subtilis CU1 during the winter months increased secretory IgA concentrations in both saliva and feces compared to placebo, suggesting it helped stimulate the mucosal immune system during a period when older adults are most vulnerable to infections.¹⁸ Fermented soybean foods in general, which owe much of their microbiology to Bacillus species, have been linked to various health benefits, though the research emphasizes that proper food safety and quality practices are essential.¹⁹

Using B. Subtilis Alongside Antibiotics

One practical question for probiotic users is whether B. subtilis can be taken at the same time as antibiotics. Because B. subtilis spores are inherently resistant to many environmental insults, they can survive antibiotic exposure in a way that most vegetative bacteria cannot. In animal studies, administering spore-based probiotics alongside antibiotics led to better restoration of gut microbiota compared to antibiotics alone, with fewer intestinal lesions and lower markers of gut barrier dysfunction.²⁰ Poultry research has similarly shown that B. subtilis supplementation during a short initial course of antibiotic growth promoters maintained growth performance and improved beneficial gut bacteria over a 16-week period.²¹ The evidence here is still mostly from animal models, but the principle that spore-based probiotics can survive antibiotic co-administration is well grounded in the biology of the organism.

Skin Applications

B. subtilis is also being explored for topical use on skin, an area where the safety profile becomes relevant in a different way. In a clinical study of people with mild-to-moderate acne, topical application of bacteriocins derived from B. subtilis for 60 days reduced the abundance of Staphylococcus aureus in acne-affected areas by about 38%. Inflammatory and non-inflammatory lesions both dropped by roughly 59% and 58% respectively compared to baseline.²²

Mouse studies have confirmed that applying live B. subtilis to skin shifts the microbial community, notably decreasing Staphylococcus while increasing Corynebacterium species.²³ Researchers looking at engineered B. subtilis as a topical drug delivery platform found that the bacteria persisted on skin for multiple days during repeated application, with little evidence of toxicity to human skin cells in lab models and no apparent safety concerns in live mice.²⁴ This is early-stage work, but it reinforces the picture of a bacterium that human tissue tolerates well even during prolonged direct contact.

The Antibiotic Resistance Concern

The most forward-looking worry about B. subtilis has nothing to do with the bacterium causing infections directly. It has to do with antibiotic resistance genes. A recent review argued that the widespread, largely unregulated use of B. subtilis in probiotics and agriculture may be contributing to the global antimicrobial resistance problem. The concern is that B. subtilis can acquire resistance genes and then transfer them horizontally to genuinely dangerous pathogens. The bacterium’s durable spores compound the issue by persisting in soil, water, and the food chain long after initial exposure.²⁵

How worried should you be? At the individual level, this is not an immediate threat. At the population level, it is worth paying attention to. Whole genome sequencing of well-characterized probiotic strains has shown that when manufacturers do their homework, the resulting strains carry no antibiotic resistance genes, virulence factors, or toxin genes that pose a risk to human health.²⁶ The problem is that not every product on the market undergoes that level of scrutiny, and environmental strains used in agriculture may not be screened as rigorously as strains destined for human consumption. The practical takeaway: if you are choosing a B. subtilis probiotic, look for products from manufacturers that specify the exact strain and can point to genomic safety data. A well-characterized strain from a reputable source is a different proposition from an unspecified “Bacillus subtilis” on a label with no strain designation.

Who Should Be Cautious

The safety data is reassuring for most adults, but a few groups should exercise more care:

• People with gut perforations or severe GI disease: A breach in the intestinal wall creates a direct path for any gut bacterium to enter the bloodstream. This is true of many organisms, not just B. subtilis, but the natto-related bacteremia cases show it is not purely theoretical.
• Premature infants with central lines: The case of catheter-related bloodstream infection in a preterm baby receiving B. subtilis probiotics suggests that central venous access combined with an immature immune system may create conditions where even a safe bacterium can cause harm.
• Severely immunocompromised individuals: As with most live microorganisms given as probiotics, people on intensive immunosuppression or those with severely weakened immune systems should discuss supplementation with their doctor before starting.
• Workers handling concentrated B. subtilis enzyme preparations: The risk here is respiratory sensitization, not infection. Proper workplace ventilation and containment are the relevant protections.

For everyone else, including healthy adults and older adults without the specific vulnerabilities listed above, the evidence consistently points to B. subtilis being safe at the doses found in food and commercially available probiotic products. The organism’s long history of safe use in fermented foods across multiple cultures, combined with its favorable regulatory status and a growing body of clinical trial data, puts it in a different category from bacteria that require serious caution.